中国临床药学杂志2025，Vol.34Issue(10)：767-771,5.DOI:10.19577/j.1007-4406.2025.10.008
CapeOx方案联合呋喹替尼治疗晚期微卫星稳定型结直肠癌的疗效及安全性
Efficacy and safety of CapeOx regimen combined with fruquintinib on advanced microsatellite stable colorectal cancer
摘要
Abstract
AIM To observe the efficacy and safety of CapeOx regimen combined with fruquintinib on advanced microsatellite stable(MSS)colorectal cancer(CRC).METHODS From September 2021 to September 2023,80 patients with advanced MSS CRC who visited our hospital were grouped through random number table.The control group(n=40)performed CapeOx regimen(oxaliplatin+capecitabine),while the research group(n=40)performed the CapeOx regimen(oxaliplatin+capecitabine)combined with fruquintinib.Efficacy,tumor markers,immune indicators,angiogenesis-related indicators,inflammatory response,security,and survival rate were compared between 2 groups.RESULTS The research group had higher objective response rate(ORR)and disease control rate(DCR)than the control group(P＜0.05).Both groups showed reduced levels of carcinoembryonic antigen,carbohydrate antigen 19-9,vascular endothelial growth factor(VEGF),interleukin-8(IL-8),C-reactive protein(CRP),and neutrophil to lymphocyte ratio(NLR)after treatment,with the research group showing lower levels than the control group(P＜0.05).After treatment,the research group had higher CD3+and CD4+counts compared to prior treatment,and the research group's counts were higher than those of the control group(P＜0.05).There was no statistically significant difference in adverse reactions between the 2 groups(P＞0.05).The research group had a higher 1-year survival rate(90.00％,36/40)than the control group(72.50％,29/40),and the difference in survival curves between the 2 groups was statistically significant(Log rank x2=4.077,P＜0.05).CONCLUSION Fruquintinib as an adjuvant therapy for advanced MSS CRC has definite efficacy.It could improve ORR,DCR and 1-year survival rate,regulate tumor markers,immune indicators and angiogenesis-related indicators,alleviate inflammatory response,and demonstrates good safety.关键词
卡培他滨/呋喹替尼/晚期/微卫星稳定型结直肠癌/疗效/安全性Key words
capecitabine/fruquintinib/advanced/microsatellite stable colorectal cancer/efficacy/security分类
药学引用本文复制引用
赵莹莹,赵如森,王永涛,辛超,冷昌俊,路支超,崔玉忠..CapeOx方案联合呋喹替尼治疗晚期微卫星稳定型结直肠癌的疗效及安全性[J].中国临床药学杂志,2025,34(10):767-771,5.基金项目
2021年度山东省医学会临床科研资金-齐鲁专项(编号YXH2022ZX02074) （编号YXH2022ZX02074）
吴阶平医学基金会临床科研专项资助基金(编号320.6750.2023-19-15) （编号320.6750.2023-19-15）
